Samsung Biologics acquires GlaxoSmithKline's US plant for 280 million dollars

Golden Longhui April 1｜Samsung Biologics, a subsidiary of the Samsung Group, announced on Wednesday that it has spent $280 million to acquire a factory in the United States from the British pharmaceutical giant GSK. Samsung Biologics stated that the factory, located in Rockville, Maryland, has a production capacity of 60,000 liters of active pharmaceutical ingredients, bringing the company's total production capacity to 845,000 liters.